Discovery and characterization of a novel highly potent and selective type II native and drug-resistant V299L mutant BCR-ABL inhibitor (CHMFL-ABL-039) for Chronic Myeloid Leukemia (CML)

BCR fused ABL kinase is the critical driving oncogene for chronic myeloid leukemia (CML) and has been extensively studied as the drug discovery target in the past decade. The successful introduction of tyrosine kinase inhibitors (TKI) such as Imatinib, Dasatinib and Bosutinib has greatly improved th...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Cancer Biol Ther
Huvudupphovsmän: Wu, Jiaxin, Wang, Aoli, Li, Xixiang, Chen, Cheng, Qi, Ziping, Hu, Chen, Wang, Wenliang, Wu, Hong, Huang, Tao, Zhao, Ming, Wang, Wenchao, Hu, Zhenquan, Liu, Qingwang, Wang, Beilei, Wang, Li, Li, Lili, Ge, Jian, Ren, Tao, Xia, Ruixiang, Liu, Jing, Liu, Qingsong
Materialtyp: Artigo
Språk:Inglês
Publicerad: Taylor & Francis 2019
Ämnen:
Research Paper
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC6606039/
https://ncbi.nlm.nih.gov/pubmed/30894066
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384047.2019.1579958
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk